TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage…
News
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, Calif., April 10,…
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of…
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies…
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral…
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a…
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual…
Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity…
Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology…